Stem cell research is developing rapidly, offering exciting possibilities for treating a variety of diseases and injuries. Two outstanding figures in this field are: mesenchymal stem cells (MSC) and induced pluripotent stem cells (iPSC).

Stem cells have become a promising candidate for treating more than 200 diseases and are conducting more than 6000 clinical trials around the world.

Is it possible to use drugs that are not yet marketed in China but can save lives for patients in domestic hospitals? Yesterday, Huashan Hospital Affiliated to Fudan University opened up a new path of medication for a patient with a rare disease.

The 14 drug clinical trial institutions (37 majors) in Shanghai City are the first batch of pilot drug clinical trial institutions to optimize the review and approval of clinical trials of innovative drugs

Nearly 35 domestic companies have deployed the iPSC field. With their high accessibility, they are expected to show huge potential in future commercialization and occupy a certain share in the market.

On August 15, the U.S. government announced the final prices of the first 10 drugs Medicare negotiated under the Inflation Reduction Act (IRA).

The characteristics of iPSC are similar to those of embryonic stem cells (ESC)-infinite expansion + tridermal cell differentiation potential.

Technical Guidelines for the Application of Decentralized Clinical Trials in Clinical Research and Development of Drugs for Rare Diseases